Vyant Bio, Inc.
vyantbio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2022 10-K, filed Mar 31, 2023. Its latest SEC filing is a DEF 14A from Aug 16, 2023.
10-K for FY2022, filed Mar 31, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops human-derived brain disease models and screening tools for pharmaceutical, biotechnology and research customers, and pursues drug candidates for rare neurological disorders.
10-K for FY2022, filed Mar 31, 2023Our central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and…View ↗
The Company’s strategy has been to utilize a unique and robust “human-first” drug discovery platform to discover repurposed and novel…View ↗
The Company began transforming its Maple Grove, Minnesota facility to a high throughput manufacturing and screening facility in the fourth…View ↗
How Did They Make Money?
Plate customers generally pay within 30 to 90 days after shipment; preclinical drug-testing services bring in revenue over the course of work on customer-supplied compounds.
10-K for FY2022, filed Mar 31, 2023
$666K
-
10-K for FY2022, filed Apr 1, 2023
$666K ↗
Who Were Their Customers?
Pharmaceutical, biotechnology and research customers bought microOrgan plates and preclinical drug-testing services; vivoPharm worked directly with preclinical teams at pharmaceutical and biotech companies.
10-K for FY2022, filed Mar 31, 2023The Company began transforming its Maple Grove, Minnesota facility to a high throughput manufacturing and screening facility in the fourth…View ↗
The Company’s primary sources of revenue are product sales from the sale of microOrgan® plates and the performance of preclinical drug…View ↗
vivoPharm’s sales and marketing efforts consist of both direct and indirect efforts, with the majority of efforts focused on direct sales…View ↗
Did Revenues Turn Into Profits?
No. It lost $22.7M in FY2022.
10-K for FY2022, filed Apr 1, 2023
−$15.9MView ↗
10-K for FY2022, filed Apr 1, 2023
−$22.7MView ↗
10-K for FY2022, filed Apr 1, 2023
−$14.3MView ↗
How Were They Changing?
-
Apr 24, 2023
Plans voluntary Nasdaq delisting and SEC deregistration
It expects shares to be quoted on OTC Pink and plans to suspend its SEC reporting obligations.
Sources
8-K, filed Apr 24, 2023
Pursuant to the Cash Preservation Plan, and after careful review and careful consideration of a number of factors, including, but not…View ↗
Shrank. Revenue fell 86% in 4 years, from $4.9M in FY2018 to $666K in FY2022, about 39% a year.
From oncology services to brain-disease drug discovery
The older report describes preclinical research services centered on oncology and immuno-oncology, while the latest emphasizes human-derived brain models and candidate drugs for neurological disorders; development programs were put on hold.
10-K for FY2019, filed May 29, 2020 10-K for FY2022, filed Mar 31, 2023
Who Did They Compete With?
Competes with Acadia Pharmaceuticals, Anavex Life Sciences, Biogen, Pfizer, Abbvie, Novartis, GlaxoSmithKline, Merck &, Eli Lilly &, Johnson & Johnson, Roche Holding, Zogenix, UCB, Cerevel Therapeutics, Corium, and Marinus Pharmaceuticals
10-K for FY2022, filed Mar 31, 2023At this time, our primary competitors are other pharmaceutical and biotechnology or biomedical development companies that are trying to…View ↗
Loading...
